Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the results of major chronic lymphocytic leukemia (CLL) trials from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Eichhorst then summarizes what the implications of these trials are in terms of the use of ibrutinib.